Sung Kwan Yoon

Title: Innovations of Sung Kwan Yoon in Humanized Antibodies

Introduction

Sung Kwan Yoon is a notable inventor based in Taejon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. His work focuses on creating therapeutic solutions for autoimmune diseases.

Latest Patents

Sung Kwan Yoon holds a patent for a humanized antibody specific for human 4-1BB. This invention is directed towards antibodies that specifically bind to the protein 4-1BB. The antibodies are developed by grafting the complementarity determining regions (CDRs) of a mouse monoclonal antibody to the human 4-1BB, along with further amino acid replacements. The resulting humanized antibody exhibits high affinity for human 4-1BB and shows sequence similarity to human antibodies. This innovation can be utilized in pharmaceutical compositions to treat autoimmune diseases and suppress immune responses with minimal side effects.

Career Highlights

Sung Kwan Yoon is associated with LG Chemical Ltd., where he continues to advance his research in antibody development. His work has the potential to significantly impact the treatment of autoimmune conditions, providing new avenues for therapeutic interventions.

Collaborations

He collaborates with notable colleagues, including Hyo Jeong Hong and Sung Sup Park, who contribute to the research and development efforts in his field.

Conclusion

Sung Kwan Yoon's innovative work in humanized antibodies represents a significant advancement in biotechnology, particularly for the treatment of autoimmune diseases. His contributions are paving the way for new therapeutic options that could improve patient outcomes.